Eli Lilly Acquires Kelonia Therapeutics in $3.2B Deal: How a Struggling Startup Secured a Biotech Giant's Takeover
Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer and autoimmune cell therapy startup, for $3.2 billion with potential milestone payments...
